Thomas Jefferson University
Goals:
Primary:
Gain unique insights into therapeutic outcomes of men with prostate cancer treated with PARP inhibitors that will inform optimal patient selection, management, and novel scientific directions.
Secondary:
Develop proposals for optimal clinical and genomic data collection to inform future PARPi candidacy and clinical practice.
Analyze responses to PARP inhibitors among prostate cancer patients with DNA repair mutations.
Develop and validate prognostic models of genomic markers on PARPi clinical outcomes
Identify genomic modifiers of PARPi response and duration of response.